Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Sarcoma 1 Resectable Esophageal Cancer 1 Pleural Mesothelial Neoplasm 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Hematologic Neoplasms 1 Colorectal Neoplasms 1

Interventions

Doxorubicin 27 pembrolizumab 24 Radiotherapy 20 Cyclophosphamide 18 Magnetic Resonance Spectroscopy 17 Specimen Handling 14 Nivolumab 14 Ifosfamide 13 Gemcitabine 13 Surgical Procedures, Operative 11 Biopsy 11 Radiation 10 Temozolomide 9 X-Rays 8 Ipilimumab 8 pazopanib 7 fludarabine 7 cabozantinib 7 Irinotecan 7 Blood Specimen Collection 7 tazemetostat 6 liposomal doxorubicin 6 Trabectedin 6 Surveys and Questionnaires 6 Phantoms, Imaging 6 olaparib 5 eribulin 5 atezolizumab 5 anlotinib 5 Vincristine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × Adjuvants, Immunologic × 1 year × Clear all

NCT03978039 2025-09-04

BCB-Sarcomes

Institut Bergonié

150,000 enrolled

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡